Literature DB >> 17545304

Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study.

Peter T E Wootton1, Nupur L Arora, Fotios Drenos, Simon R Thompson, Jackie A Cooper, Jeffrey W Stephens, Steven J Hurel, Eva Hurt-Camejo, Olov Wiklund, Steve E Humphries, Philippa J Talmud.   

Abstract

Animal and human studies suggest that both secretory PLA2 (sPLA2)-V and sPLA2-IIA (encoded, respectively, by the neighbouring PLA2G5 and PLA2G2A genes) contribute to atherogenesis. Elevated plasma sPLA2-IIA predicts coronary heart disease (CHD) risk, but no mass assay for sPLA2-V is available. We previously reported that tagging single nucleotide polymorphism (tSNP) haplotypes of PLA2G2A are strongly associated with sPLA2-IIA mass, but not lipid levels. Here, we use tSNPs of the sPLA2-V gene to investigate the association of PLA2G5 with CHD risk markers. Seven PLA2G5 tSNPs genotypes, explaining >92% of the locus genetic variability, were determined in 519 patients with Type II diabetes (in whom PLA2G2A tSNP data was available), and defined seven common haplotypes (frequencies >5%). PLA2G5 and PLA2G2A tSNPs showed linkage disequilibrium (LD). Compared to the common PLA2G5 haplotype, H1 (frequency 34.9%), haplotypes H2-7 were associated with overall higher plasma LDL (P < 0.00004) and total cholesterol (P < 0.00003) levels yet lower oxLDL/LDL (P = 0.006) and sPLA2-IIA mass (P = 0.04), probably reflecting LD with PLA2G2A. Intronic tSNP (rs11573248), unlikely itself to be functional, distinguished H1 from LDL-raising haplotypes and may mark a functional site. In conclusion, PLA2G5 tSNP haplotypes demonstrate an association with total and LDL cholesterol and oxLDL/LDL, not seen with PLA2G2A, thus confirming distinct functional roles for these two sPLA2s.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17545304     DOI: 10.1093/hmg/ddm094

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  18 in total

1.  Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.

Authors:  Hiroyasu Sato; Rina Kato; Yuki Isogai; Go-ichi Saka; Mitsuhiro Ohtsuki; Yoshitaka Taketomi; Kei Yamamoto; Kae Tsutsumi; Joe Yamada; Seiko Masuda; Yukio Ishikawa; Toshiharu Ishii; Tetsuyuki Kobayashi; Kazutaka Ikeda; Ryo Taguchi; Shinji Hatakeyama; Shuntaro Hara; Ichiro Kudo; Hiroyuki Itabe; Makoto Murakami
Journal:  J Biol Chem       Date:  2008-09-18       Impact factor: 5.157

2.  Biallelic mutations in PLA2G5, encoding group V phospholipase A2, cause benign fleck retina.

Authors:  Panagiotis I Sergouniotis; Alice E Davidson; Donna S Mackay; Eva Lenassi; Zheng Li; Anthony G Robson; Xu Yang; Jaimie Hoh Kam; Timothy W Isaacs; Graham E Holder; Glen Jeffery; Jonathan A Beck; Anthony T Moore; Vincent Plagnol; Andrew R Webster
Journal:  Am J Hum Genet       Date:  2011-12-01       Impact factor: 11.025

3.  A new era of secreted phospholipase A₂.

Authors:  Makoto Murakami; Hiroyasu Sato; Yoshimi Miki; Kei Yamamoto; Yoshitaka Taketomi
Journal:  J Lipid Res       Date:  2015-03-24       Impact factor: 5.922

4.  Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels.

Authors:  Michael V Holmes; Holly J Exeter; Lasse Folkersen; Christopher P Nelson; Montse Guardiola; Jackie A Cooper; Reecha Sofat; S Matthijs Boekholdt; Kay-Tee Khaw; Ka-Wah Li; Andrew J P Smith; Ferdinand Van't Hooft; Per Eriksson; Anders Franco-Cereceda; Folkert W Asselbergs; Jolanda M A Boer; N Charlotte Onland-Moret; Marten Hofker; Jeanette Erdmann; Mika Kivimaki; Meena Kumari; Alex P Reiner; Brendan J Keating; Steve E Humphries; Aroon D Hingorani; Ziad Mallat; Nilesh J Samani; Philippa J Talmud
Journal:  Circ Cardiovasc Genet       Date:  2014-02-21

5.  Molecular and functional characterization of polymorphisms in the secreted phospholipase A2 group X gene: relevance to coronary artery disease.

Authors:  Sarah Gora; Claire Perret; Ikram Jemel; Viviane Nicaud; Gérard Lambeau; François Cambien; Ewa Ninio; Stefan Blankenberg; Laurence Tiret; Sonia-Athina Karabina
Journal:  J Mol Med (Berl)       Date:  2009-06-03       Impact factor: 4.599

Review 6.  Role of secretory phospholipases in atherogenesis.

Authors:  Ann-Cathrine Jönsson-Rylander; Sofia Lundin; Birgitta Rosengren; Camilla Pettersson; Eva Hurt-Camejo
Journal:  Curr Atheroscler Rep       Date:  2008-06       Impact factor: 5.113

7.  The adipocyte-inducible secreted phospholipases PLA2G5 and PLA2G2E play distinct roles in obesity.

Authors:  Hiroyasu Sato; Yoshitaka Taketomi; Ayako Ushida; Yuki Isogai; Takumi Kojima; Tetsuya Hirabayashi; Yoshimi Miki; Kei Yamamoto; Yasumasa Nishito; Tetsuyuki Kobayashi; Kazutaka Ikeda; Ryo Taguchi; Shuntaro Hara; Satoshi Ida; Yuji Miyamoto; Masayuki Watanabe; Hideo Baba; Keishi Miyata; Yuichi Oike; Michael H Gelb; Makoto Murakami
Journal:  Cell Metab       Date:  2014-06-05       Impact factor: 27.287

8.  The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).

Authors:  Zory Shaposhnik; Xuping Wang; Joaquim Trias; Heather Fraser; Aldons J Lusis
Journal:  J Lipid Res       Date:  2008-11-21       Impact factor: 5.922

Review 9.  Secreted phospholipase A2, lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics.

Authors:  Kei Yamamoto; Yuki Isogai; Hiroyasu Sato; Yoshitaka Taketomi; Makoto Murakami
Journal:  Anal Bioanal Chem       Date:  2011-03-29       Impact factor: 4.142

Review 10.  Integrated lipidomics in the secreted phospholipase A(2) biology.

Authors:  Makoto Murakami; Hiroyasu Sato; Yoshitaka Taketomi; Kei Yamamoto
Journal:  Int J Mol Sci       Date:  2011-02-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.